{
    "clinical_study": {
        "@rank": "40285", 
        "acronym": "EMGEL", 
        "arm_group": [
            {
                "arm_group_label": "Morphine gel", 
                "arm_group_type": "Experimental", 
                "description": "morphine 30 mg, quantity of gel per application: 15mg (15ml)"
            }, 
            {
                "arm_group_label": "Neutral gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "water for injection, quantity of gel per application: 15mg (15ml)"
            }
        ], 
        "brief_summary": {
            "textblock": "This phase III study aims to show that topical morphine low doses treats localized pain in\n      chronic wounds, intense and rebellious to systemic analgesics included or not opioids."
        }, 
        "brief_title": "Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Local Pain", 
            "Chronic Wounds"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged over 18 years\n\n          -  Painful chronic wounds (bedsores, wound tumor, arterial ulcers, venous or mixed\n             diabetic ulcer if systolic pressure index >0.8, necrotic angiodermatitis not\n             graftable), a bottom surface 300 cm\u00b2 and does not require more than 15 ml of gel by\n             application. When patient has multiple painful chronic wounds, the wound having only\n             the highest pain intensity is considered for evaluation.\n\n          -  Ineffective systemic analgesic with or without opioid analgesic established and\n             maintained at the same dose for 3 days before inclusion. If treatment includes\n             morphine, the daily dose should not exceed 60 mg of morphine equivalent and this\n             treatment must be a treatment exclusive background.\n\n          -  Patient requiring an analgesic equilibration for intense and rebellious local pain,\n             with a daily average score greater than or equal to 5, on a graduated numerical scale\n             of 0 to 10. The score is defined at the inclusion and corresponds to the pain\n             intensity felt locally by the patient under treatment systemic analgesic with or\n             without co-analgesics.\n\n          -  If analgesics to treat systemic pain is ongoing, it must have been introduced for\n             more than 3 days (according to criteria 3)\n\n          -  If antidepressant treatment is in progress, it must have been established for over a\n             month for a tricyclic and for more than 15 days for other classes of antidepressants.\n\n          -  If an anti-epileptic treatment analgesic is in progress, it must have been\n             established for over 15 days.\n\n          -  Signing of the informed consent form.\n\n          -  Patient able to respond the self-assessment questionnaires (sufficient understanding\n             assessments, proficiency in French).\n\n          -  Patient affiliated to an health insurance plan\n\n        Exclusion Criteria:\n\n          -  Allergy to morphine or carboxymethylcellulose or history of intolerance to morphine\n\n          -  Analgesic at baseline including systemic morphine to greater than 60 mg equivalent\n             dose of morphine treatment\n\n          -  Fistulated wound\n\n          -  Heavily exuding wound\n\n          -  Wound bleeding (spontaneous bleeding)\n\n          -  Ongoing radiotherapy on chronic wound\n\n          -  Creatinine > 110 \u00b5mol/L, Total bilirubin > 20 \u00b5mol/L\n\n          -  Not communicating patient\n\n          -  Unable to comply with requirement of the protocol (11 days)\n\n          -  Patient pregnant or of childbearing age without contraceptive therapy or lactating\n\n          -  Person deprived of liberty or under guardianship\n\n          -  Only for pharmacokinetic analysis: analgesics at baseline including morphine or\n             hydromorphone or oxycodone or codeine. Fentanyl is allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028923", 
            "org_study_id": "IC 2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Morphine gel", 
                "description": "Topical", 
                "intervention_name": "Morphine gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neutral gel", 
                "description": "Topical", 
                "intervention_name": "Neutral gel", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "topical morphine", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Philippe Charru, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Colombes", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "92700"
                    }, 
                    "name": "H\u00f4pital Louis Mourier"
                }, 
                "investigator": {
                    "last_name": "Philippe Charru, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "irene.kriegel@curie.fr", 
                    "last_name": "Ir\u00e8ne KRIEGEL, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }, 
                "investigator": {
                    "last_name": "Ir\u00e8ne Kriegel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nathalie Faucher, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "75877"
                    }, 
                    "name": "Groupe Hospitalier Bichat"
                }, 
                "investigator": {
                    "last_name": "Nathalie Faucher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Julia Revnic, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "75019"
                    }, 
                    "name": "H\u00f4pital Jean-Jaur\u00e8s"
                }, 
                "investigator": {
                    "last_name": "Julia Revnic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "virginie.laurent@curie.fr", 
                    "last_name": "Virginie Laurent, MD", 
                    "phone": "33147111515"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Cloud", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "92210"
                    }, 
                    "name": "Institut Curie - H\u00f4pital Ren\u00e9 Huguenin"
                }, 
                "investigator": {
                    "last_name": "Virginie Laurent, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds", 
        "overall_contact": {
            "email": "patricia.tresca@curie.fr", 
            "last_name": "Patricia TRESCA, Leader", 
            "phone": "33156245630"
        }, 
        "overall_contact_backup": {
            "email": "isabelle.turbiez@curie.fr", 
            "last_name": "Isabelle TURBIEZ, Manager", 
            "phone": "33147111659"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut Curie - H\u00f4pital Ren\u00e9 Huguenin", 
                "last_name": "Laurent Virginie, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Curie - Paris", 
                "last_name": "Audrey Hurgon, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg (either up to 3 tablets 10 mg per day) for the last 72 hours of the study (day 8 to day 11) and for which the basic treatment is unchanged throughout the duration of the study", 
            "measure": "Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg for the last 72 hours of the study", 
            "safety_issue": "No", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction in average daily pain intensity score on a numerical rating scale (where 0=no pain and 10=worst possible pain) self assessment, measured on an 11-point between day 1 and day 11. Therefore patients evaluate each morning local pain of the previous 24 hours.", 
                "measure": "Reduction in average daily pain intensity score on a numerical rating scale self assessment, measured on an 11-point between day 1 and day 11", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Evaluate the percentage of local pain relief for 24 hours on a rating scale from 0 to 100%", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Assess and characterize the evolution of local pain on a global impression scale change : Pain related Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Assess patient satisfaction with treatment of local pain (score 0-4)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "description": "0% no impact of pain on sleep 100% maximum impact of pain on sleep, inability to sleep", 
                "measure": "Evaluate the impact score of local pain on sleep (self-report scale of 0 to 100%)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Determine the time (in hours) before using oral immediate-release morphine after application of local treatment", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Determination of cumulative dose of oral immediate-release morphine (in milligrams) of the 11 days of treatment for relieving painful access of local origin", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Evaluate systemic and local side effects of analgesic treatment (incidence, severity and location)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Evaluate the systemic absorption of topical morphine blood test after the first application", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }
        ], 
        "source": "Institut Curie", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Centre Rene Huguenin", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "H\u00f4pital Louis Mourier", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Institut Curie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}